Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-FALMIN for Albumin Supplementation in Pulmonary Tuberculosis
NCT07186478Active, not recruiting
- Sponsor
- Hasanuddin University
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of I-Falmin in pulmonary tuberculosis (TB) (2 arms), sponsored by Hasanuddin University. Primary endpoints: Change in serum albumin concentration at Day 15 and Change in Body Mass Index at Day 57. Started Dec 2024; status: active, not recruiting.
02
Drugs
I-Falmin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT07186478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186478.